ADAT2: A Potential Drug Target and Biomarker for tRNA-Specific Deaminase
		ADAT2: A Potential Drug Target and Biomarker for tRNA-Specific Deaminase
Abstract:
Adenosine deaminase (ADAT2) is a protein that plays a crucial role in the regulation of DNA methylation. Mutations in the ADAT2 gene have been associated with various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Despite its importance, the research on ADAT2 has been limited, and there is a need for more research on its functions and potential as a drug target or biomarker. In this article, we will explore the functions of ADAT2, its potential as a drug target, and its potential as a biomarker for various diseases.
Introduction:
Adenosine deaminase (ADAT2) is a protein that is expressed in various tissues and cells of the body. It is a key enzyme in the DNA methylation pathway, which is responsible for the regulation of gene expression and cell development. The ADAT2 gene has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Despite its importance, the research on ADAT2 has been limited, and there is a need for more research on its functions and potential as a drug target or biomarker.
Functions of ADAT2:
ADAT2 is a key enzyme in the DNA methylation pathway. It is responsible for the deamination of adenosine to its active form, adenosine monophosphate (AMP), which can then be converted to adenosine triphosphate (ATP). The DNA methylation pathway is a complex process that involves various enzymes and proteins. ADAT2 is one of the key enzymes that is involved in the regulation of gene expression and cell development.
ADAT2 has also been shown to play a role in the regulation of cellular processes, including cell apoptosis, cell cycle progression, and DNA replication. It has been shown to regulate the expression of genes that are involved in cell growth, differentiation, and apoptosis. Additionally, ADAT2 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway.
Potential as a Drug Target:
ADAT2 has been shown to be a potential drug target for various diseases. Its functions in the DNA methylation pathway and its involvement in cellular processes make it an attractive target for therapeutic intervention.
One of the potential mechanisms by which ADAT2 can be targeted is through its role in the regulation of gene expression. By regulating the expression of genes that are involved in cancer, neurodegenerative diseases, and developmental disorders, ADAT2 can be thought of as a potential drug target for these diseases. Additionally, ADAT2 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. Targeting ADAT2 with small molecules or antibodies that can modulate its activity could lead to therapeutic intervention for diseases that are currently treated with drugs that target these signaling pathways.
Potential as a Biomarker:
ADAT2 has the potential to serve as a biomarker for various diseases. Its involvement in the DNA methylation pathway and its potential as a drug target make it an attractive candidate for biomarker development.
One of the potential applications of ADAT2 as a biomarker is its potential to serve as a biomarker for cancer. The DNA methylation pathway has been shown to play a critical role in the regulation of cancer development and progression. By regulating the expression of genes that are involved in the DNA methylation pathway, ADAT2 can be thought of as a potential biomarker for cancer. Additionally, ADAT2 has been shown to play a role in the regulation of cellular signaling pathways, including the TGF-β pathway. Targeting ADAT2 with small molecules or antibodies that can modulate its activity could lead to therapeutic intervention for
Protein Name: Adenosine Deaminase TRNA Specific 2
Functions: Probably participates in deamination of adenosine-34 to inosine in many tRNAs
		
More Common Targets
ADAT3 | ADCK1 | ADCK2 | ADCK5 | ADCY1 | ADCY10 | ADCY10P1 | ADCY2 | ADCY3 | ADCY4 | ADCY5 | ADCY6 | ADCY7 | ADCY8 | ADCY9 | ADCYAP1 | ADCYAP1R1 | ADD1 | ADD2 | ADD3 | ADD3-AS1 | Adducin | Adenosine A2 receptor | Adenosine deaminase | Adenosine receptor | Adenylate Cyclase | ADGB | ADGB-DT | ADGRA1 | ADGRA2 | ADGRA3 | ADGRB1 | ADGRB2 | ADGRB3 | ADGRB3-DT | ADGRD1 | ADGRD2 | ADGRE1 | ADGRE2 | ADGRE3 | ADGRE4P | ADGRE5 | ADGRF1 | ADGRF2 | ADGRF3 | ADGRF4 | ADGRF5 | ADGRG1 | ADGRG2 | ADGRG3 | ADGRG4 | ADGRG5 | ADGRG6 | ADGRG7 | ADGRL1 | ADGRL1-AS1 | ADGRL2 | ADGRL3 | ADGRL4 | ADGRV1 | ADH1A | ADH1B | ADH1C | ADH4 | ADH5 | ADH5P4 | ADH6 | ADH7 | Adhesion G-protein coupled receptor G1 (isoform a) | ADHFE1 | ADI1 | ADIG | ADIPOQ | ADIPOQ-AS1 | ADIPOR1 | ADIPOR2 | ADIRF | ADK | ADM | ADM-DT | ADM2 | ADM5 | ADNP | ADNP2 | ADO | ADORA1 | ADORA2A | ADORA2A-AS1 | ADORA2B | ADORA3 | ADP-Ribosylation Factor | ADPGK | ADPGK-AS1 | ADPRH | ADPRHL1 | ADPRM | ADPRS | ADRA1A | ADRA1B | ADRA1D
 
        